GSK terminates its Alector pact after back-to-back Phase 2/3 flops in dementia and Alzheimer's, leaving Alector's pipeline preclinical-only.
July 9, 2026 06:51 AM EDT
DealsPharma
GSK walks away from Alector pact as immuno-neurology bet fizzles
Ayisha Sharma
News Reporter
GSK ends brain drug alliance with Alector
GSK Adds Positive Phase 3 Lung Cancer Data, Ends Alector Partnership - GSK (NYSE:GSK)
Bristol lays out KRAS med Krazati's stumble in confirmatory colorectal cancer trial
GSK, Hansoh ADC extends survival in lung cancer study
AZ, Ionis shares tumble on ATTR-CM trial flop, but analyst flags over-reaction
GSK to seek FDA approval for Jemperli in small but high-profile cancer use after phase 2 win
AstraZeneca's trial flop raises a bigger question: Is its pipeline premium becoming more vulnerable?
